Literature DB >> 35092809

Toxicity of high-molecular-weight polyethylene glycols in Sprague Dawley rats.

Jia-Long Fang1, Michelle M Vanlandingham2, Frederick A Beland2, Robert P Felton3, Mackean P Maisha3, Greg R Olson4, Ralph E Patton4, Amy S Rosenberg5, Gonçalo Gamboa da Costa2.   

Abstract

Polyethylene glycol (PEG) is present in a variety of products. Little is known regarding the accumulation of high-molecular-weight PEGs or the long-term effects resulting from PEG accumulation in certain tissues, especially the choroid plexus. We evaluated the toxicity of high-molecular-weight PEGs administered to Sprague Dawley rats. Groups of 12 rats per sex were administered subcutaneous injections of 20, 40, or 60 kDa PEG or intravenous injections of 60 kDa PEG at 100 mg PEG/kg body weight/injection once a week for 24 weeks. A significant decrease in triglycerides occurred in the 60 kDa PEG groups. PEG treatment led to a molecular-weight-related increase in PEG in plasma and a low level of PEG in cerebrospinal fluid. PEG was excreted in urine and feces, with a molecular-weight-related decrease in the urinary excretion. A higher prevalence of anti-PEG IgM was observed in PEG groups; anti-PEG IgG was not detected. PEG treatment produced a molecular-weight-related increase in vacuolation in the spleen, lymph nodes, lungs, and ovaries/testes, without an inflammatory response. Mast cell infiltration at the application site was noted in all PEG-treated groups. These data indicate that subcutaneous and intravenous exposure to high-molecular-weight PEGs produces anti-PEG IgM antibody responses and tissue vacuolation without inflammation.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-PEG antibody; Choroid plexus; Polyethylene glycol; Vacuolation

Mesh:

Substances:

Year:  2022        PMID: 35092809      PMCID: PMC8932377          DOI: 10.1016/j.toxlet.2022.01.011

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  42 in total

1.  A method for the estimation of polyethylene glycol in plasma protein fractions.

Authors:  G E Sims; T J Snape
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

2.  Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.

Authors:  T L Cheng; B M Chen; J W Chern; M F Wu; S R Roffler
Journal:  Bioconjug Chem       Date:  2000 Mar-Apr       Impact factor: 4.774

3.  Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Authors:  John S Sundy; Herbert S B Baraf; Robert A Yood; N Lawrence Edwards; Sergio R Gutierrez-Urena; Edward L Treadwell; Janitzia Vázquez-Mellado; William B White; Peter E Lipsky; Zeb Horowitz; William Huang; Allan N Maroli; Royce W Waltrip; Steven A Hamburger; Michael A Becker
Journal:  JAMA       Date:  2011-08-17       Impact factor: 56.272

Review 4.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates.

Authors:  Paolo Caliceti; Francesco M Veronese
Journal:  Adv Drug Deliv Rev       Date:  2003-09-26       Impact factor: 15.470

5.  Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  M M Kurfürst
Journal:  Anal Biochem       Date:  1992-02-01       Impact factor: 3.365

Review 6.  PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.

Authors:  Inge A Ivens; William Achanzar; Andreas Baumann; Annamaria Brändli-Baiocco; Joy Cavagnaro; Maggie Dempster; B Olympe Depelchin; Armando R Irizarry Rovira; Laura Dill-Morton; Joan H Lane; Birgit M Reipert; Theodora Salcedo; Becky Schweighardt; Laurie S Tsuruda; Peter L Turecek; Jennifer Sims
Journal:  Toxicol Pathol       Date:  2015-08-03       Impact factor: 1.902

7.  Size exclusion chromatography with Corona charged aerosol detector for the analysis of polyethylene glycol polymer.

Authors:  Dawen Kou; Gerald Manius; Shangdong Zhan; Hitesh P Chokshi
Journal:  J Chromatogr A       Date:  2009-05-21       Impact factor: 4.759

8.  Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.

Authors:  Nancy J Ganson; Susan J Kelly; Edna Scarlett; John S Sundy; Michael S Hershfield
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats.

Authors:  Masako Ichihara; Taro Shimizu; Ami Imoto; Yuki Hashiguchi; Yumi Uehara; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Pharmaceutics       Date:  2010-12-27       Impact factor: 6.321

10.  Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice.

Authors:  Tien-Ching Chang; Bing-Mae Chen; Wen-Wei Lin; Pei-Hua Yu; Yi-Wen Chiu; Yuan-Tsong Chen; Jer-Yuarn Wu; Tian-Lu Cheng; Daw-Yang Hwang; And Steve Roffler
Journal:  Pharmaceutics       Date:  2019-12-21       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.